Verquvo
My Prescription
Payment
Select pharmacy
$698.49
Print or send this coupon to your phone
AlbertsonsPowered byAbout Verquvo
Drug Details
Vericiguat, marketed under the brand name Verquvo, is prescribed for adults dealing with chronic heart failure. Its primary purpose is to reduce the risk of mortality and decrease the likelihood of hospitalization due to heart issues. This medication is especially beneficial for patients who continue to exhibit heart failure symptoms after recent hospitalizations or when they require injectable heart failure treatments. Vericiguat functions by activating a protein known as soluble guanylate cyclase (sGC), which helps relax and dilate blood vessels, allowing blood to circulate more efficiently. This process eases the burden on the heart, enabling it to pump blood more effectively and with less exertion.
Price history for Verquvo
30 Tablets, 5MG
Average retail price for Verquvo
Average SaveHealth price for Verquvo
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Verquvo dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 2.5MG | 1 Tablet | $28.94 | $28.94 |
| 2.5MG | 14 Tablets | $335.06 | $23.93 |
| 2.5MG | 30 Tablets | $698.56 | $23.29 |
| 2.5MG | 100 Tablets | $2,288.86 | $22.89 |
| 5MG | 30 Tablets | $698.69 | $23.29 |
| 5MG | 1 Tablet | $28.94 | $28.94 |
| 5MG | 14 Tablets | $335.12 | $23.94 |
Verquvo FAQs
Verquvo is used to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction less than 45%. It is typically prescribed for patients who have recently been hospitalized for heart failure or require outpatient intravenous diuretics.
Verquvo and Entresto are not the same medication. Verquvo contains the active ingredient vericiguat, while Entresto is a combination of sacubitril and valsartan. Both are used to treat heart failure, but they work through different mechanisms. It is important for patients to follow their healthcare provider's guidance on which medication is appropriate for their condition.
Verquvo (vericiguat) is not specifically indicated to improve ejection fraction. It is used to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. While it may help manage symptoms and reduce hospitalizations, its primary benefit is not directly improving ejection fraction.
If a patient stops taking Verquvo (vericiguat) without consulting their healthcare provider, their heart failure symptoms may worsen. It is important for patients to follow their healthcare provider's instructions regarding medication use and to discuss any concerns or side effects they may be experiencing. Stopping the medication abruptly could lead to a deterioration in their condition.
Vericiguat is primarily used to reduce the risk of cardiovascular death and heart failure hospitalization in patients with symptomatic chronic heart failure and reduced ejection fraction. While it helps manage symptoms and outcomes in heart failure, it does not directly improve ejection fraction.